trending Market Intelligence /marketintelligence/en/news-insights/trending/7fvkblfcjxzyjagueigt5g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioSig Technologies seeks US FDA approval for cardiac recording system

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioSig Technologies seeks US FDA approval for cardiac recording system

BioSig Technologies Inc. filed a 510(k) application with the U.S. Food and Drug Administration for its PURE EP System.

The Los Angeles-based medical device company is seeking approval for the surface electrocardiogram and intracardiac multichannel recording system, which aims to produce high-fidelity heart recordings during electrophysiology studies and catheter ablation procedures.

Catheter ablation is a procedure to treat atrial fibrillation, the most common form of quivering or irregular heartbeat known as arrhythmia. Atrial fibrillation affects 6.1 million people in the U.S., increasing their risk of stroke by 4 to 5 times.

BioSig Technologies said it has conducted 11 pre-clinical studies and one clinical trial between 2015 and 2018.